Objective: To establish the birth prevalence of sickle cell disease in Grenada, with a view to assess the requirement for a population-based neonatal screening programme. 
Sickle cell disease (SCD) is a significant problem in the Caribbean, where many individuals have African and Asian ancestors. The first case of SCD, reported by James Herrick, 1 was a patient from Grenada. Data on the epidemiology and prevalence of SCD are unavailable in many Caribbean countries, including Grenada. To overcome this, closer collaboration between Caribbean territories initiated in 2006 led to the formation of the Caribbean Network of Researchers on Sickle Cell Disease and Thalassemia (CAREST). SCD newborn screening forms part of the priority programmes developed by CAREST. 2 There is definitive evidence from Caribbean countries with experience in SCD management, such as Jamaica and Guadeloupe, that newborn screening and relatively inexpensive interventions in early life decrease mortality and morbidity in infants with SCD. 3, 4 SCD patients in Grenada, currently diagnosed when presenting with crisis, are managed through collaboration with the Pediatric Department of the General Hospital Grenada, the Sickle Cell Association of Grenada (SCAG) and Community Health Services. All identified cases of SCD are reported to SCAG, and referred to the monthly sickle cell clinic at the St. George's Health Center in the capital, St. George's. The Clinic, run by a member of the pediatric team, a representative from SCAG, and a community health nurse, is supported by the Hospital Laboratory Services and the Government of Grenada Pharmacy Services.
To establish the local SCD birth prevalence and to foster newborn screening in Grenada, CAREST offered subsidized newborn screening for a two-year period. A partnership coordinated by CAREST was established with the SCAG, the Ministry of Health of Grenada, and the diagnostic laboratory of haemoglobinopathies of the University Hospital of Guadeloupe. In Guadeloupe, there is solid experience in newborn screening with a universal screening programme for SCD and other abnormal haemoglobins in place since 1984. 5 The laboratory has also provided neonatal screening services for another Caribbean country, Tobago. 2 The pilot study was undertaken at the principal delivery site of Grenada, the General Hospital, from 1 March 2014 to 15 November 2015. Mothers gave verbal consent for the blood tests, which were collected on Guthrie test cards and sent to the Guadeloupe Laboratory. During this period, 1923 blood specimens, representing 79% of the births, were collected and sent for analysis. A brief decrease in vigilance in the collection of the blood specimens at the mid-point of the programme was corrected, but had an impact on the birth coverage rate. Initial haemoglobin screening was carried out using high performance liquid chromatography (Variant TM nbs Newborn Hemoglobin system-Bio Rad), with isoelectric focusing (PerkinElmer) as a confirmatory test.
Of the 1923 samples taken, nine could not be analyzed, seven because of an insufficient quantity of analyzable material, and the other two because the sample listing and the information on the Guthrie cards did not correspond. Using the combination of the two screening methods, 1914 samples could be tested. The results showed 1653 babies with a normal FA pattern, 183 with an FAS pattern (consistent with sickle cell carrier), 63 with an FAC pattern (consistent with haemoglobin C carrier), 10 with an FS pattern (consistent with sickle cell disease), and 2 with an FSC pattern (consistent with haemoglobin SC disease). This corresponds to birth prevalences (90% confidence interval) of 9.56% (7.96%-11.44%) for Hb FAS, 3.29% (2.39%-4.52%) for Hb FAC, 0.52% (0.23%-1.16%) for Hb FS, and 0.10% (0.02%-0.54%) for Hb FSC. These data indicated that SCD was diagnosed for 1 in 160 newborns (see Table 1 ). This birth prevalence, higher than that observed in the French West-Indies, is closer to that observed in Jamaica.
The families of the babies diagnosed with SCD are educated on the disease and its clinical management. The babies are started on folic acid and pen VK prophylaxis and receive immunization under the Grenada Expanded Program on Immunization, with an additional pneumococcal 23 at age two. Follow-up is carried out at the Sickle Cell Clinic on a three monthly basis, and also as the need arises depending on the clinical picture. The 12 children diagnosed with SCD through the pilot screening programme were all called into clinical care according to this protocol.
This pilot study demonstrated the feasibility of neonatal screening for SCD and subsequent follow-up of the diagnosed babies. On the basis of the information regarding the birth prevalence of SCD in Grenada provided by this study, the Health Ministry of Grenada is committed to engage this strategy, focusing on early diagnosis and access to care, in order to successfully reduce the burden of SCD in Grenada. SCD is currently perceived as a significant problem in the Grenadian healthcare system, and the Government is firmly resolved to continue the screening programme and to ensure its funding. A formal agreement between the parties is under development to define the screening and medical follow up conditions. 
